The £12 at-home prostate cancer test that could save you weeks of waiting for a GP

It's a slightly odd moment when I fire the little spring-loaded lancet into my own hand and, despite my attempts to bleed neatly, the kitchen table takes on a crime-scene feel. I've waited until family members are out and I'm able to process results alone, decide on next steps, and set my face if needed.
I'm taking a prostate health blood test that I bought in Sainsbury's. It uses the little white plastic result tray familiar from Covid, capturing a drop of blood. The makers of the test I'm using say take up has increased 69 per cent since launch, two years ago. More and more of us are checking ourselves in this way, but what does it entail and what do you need to know?
There is something satisfying about taking some control of your own health, and that's how it feels to take a prostate health test in your kitchen. It requires some self-education and a little caution, but I'm a fan. There are two kinds currently available – the pin-prick quick response that I am trying, and those that require a larger sample to be sent to a lab. Other commercial screenings exist, but have not been rolled out for home use yet.
The commercial laboratory tests are much the same as an NHS blood test, only without the doctor to interpret results and place them in context (many provide this as an optional extra). Both measure PSA, a naturally occurring protein that can be an indicator of cancer.
Testing at home for medical conditions is a booming business, with the global at-home medical testing market estimated at $7.4 million (£5.5m) in 2024.
I have to confess, the idea of peering into my health in the privacy of my own home is very appealing – especially while there is no national screening programme. The faff of arranging appointments, the vulnerable feeling that overtakes you as you walk through the door of the surgery, and the worry about managing feelings: all of this makes lightly stabbing myself at the kitchen table feel more than worth it.
Pros of self-test kits
They are (reasonably) accurate
Nick James, professor of prostate and bladder cancer research at the Institute of Cancer Research, and the Royal Marsden Hospital in London says, 'We did a bit of research on tests of this type and they weren't bad, to be honest. We dual-tested 50-100 [patients], comparing our lab results with their results – there was some inaccuracy at the borderline between normal and abnormal, but did that matter? Probably not. Once you have a properly abnormal PSA they will be accurate'.
They are quick
Prof James says: 'It is quite a good way of circumventing the initial chat with the GP. Most things in life you have control of, you want a pizza you pick up the phone and it arrives. It's only in medicine where you have to be grateful for what the NHS gives you, which might be great or it might be rubbish.'
They are a useful start
'There's not much you can do wrong with them really,' says Prof James. 'If you have the test and it's normal, probably the NHS test would be normal too, if it's abnormal that should allow you to drive a referral. I tried to get an NHS PSA just to see the process, and it took me weeks and weeks.'
They are cheap and easy
Frederick Manduca is a director of Newfoundland Diagnostics, which makes the lateral flow PSA test I used. He says: 'There's a convenience factor, you can buy the test in Sainsbury's with your shopping and the result is there within ten minutes. It retails at £12, so you can screen regularly. It's easy to use. You only need a few droplets of blood and you can put it through the lateral flow test.'
They are set up for the most at-risk group
Newfoundland tests record any PSA score up to four as normal. 'We chose four as the dividing line,' says Manduca. 'It's all based on what we see as the most helpful cut-off for age. If we were screening 20-40 year olds the cut off would be much lower, but because that group is at such low risk, we weren't focused on them. At 70-plus, an abnormal result comes in between 4 and 5 PSA, between 50 and 70, anything from 4.00 upwards is definitely raised. It's the mid-point for that age range.'
Cons of self-test kits
Interpreting the results
It's about self-education. PSA is not a cancer indicator in itself. Manduca says: 'The key is people understanding when they should test and what the results mean – this is a test for a protein the body produces, it's not a test for prostate cancer.' The Newfoundland tests come with a leaflet produced in conjunction with a cancer charity.
How do the self-test kits compare to a clinical screening?
There has been some controversy about this. A BBC report into the rapid response tests (no brands were specified) said: 'Of the five kits analysed by the BBC, one did not produce a readable result; three came back all clear; but one did show a solid dark line, indicating a PSA level above 4.0 ug/l. A private blood test taken the same day and sent to a laboratory, showed a much lower reading of 0.27 ug/l.'
Manduca says the Newfoundland kits are tested against approved independent lab results: '92 per cent of the time the lab tests and the rapid tests were agreeing. There are slight deviations and cut-offs, if you were right on a boundary number, say 3.9.'
He warns, however, that there are less reliable tests sold online and consumers need to check for official approvals before buying.
The Prostate Cancer UK site says: 'We recommend that if you're worried about prostate cancer and want a PSA blood test, you should speak to your GP. It's crucial that, before you have a PSA blood test, you get balanced information or counselling from a healthcare professional, and that you get professional follow-up about your result and what to do next.'
How to read your self-test kit results
Any PSA is far from conclusive. Using a cheap and reasonably accurate home test can allow you to track your number and spot any changes. An NHS PSA test is also not definitive, and a high number should mark the start of an investigation. Figures for 'normal' PSA scores by age are available online, but any worries need full investigation with MRI scans via the doctor.
Fredrick Manduca says: 'It's a tool in an overall toolkit. A lot of men don't know that if do they have a raised PSA only one-in-four of them will have prostate cancer. The general concept is for someone to test every year or every two years depending on how at risk they are, and see if there's a change.'
My test, by the way, was normal, matching my most recent PSA which came in under 4.00. But I shall continue to monitor myself, looking for tell-tale changes.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

The Independent

39 minutes ago

• The Independent

Mounjaro weight loss jab: What you need to know as NHS changes prescription rules

GPs across England will, for the first time, be able to prescribe a new weight loss injection on the NHS from Monday, as the health service embarks on a significant mass rollout. The medication, Mounjaro, is also known as tirzepatide and manufactured by Lilly. It is expected to be made available to approximately 220,000 individuals identified as having the "greatest need" for treatment. The drug was previously only accessible to patients through a specialist weight loss service or through private healthcare services. This initial phase of the programme is projected to span the next three years, integrating the new drug into primary care. Here is a look at Mounjaro and its effects. How does tirzepatide work? Tirzepatide, or Mounjaro, is an anti-diabetic drug. It lowers which blood sugar levels and slows down how quickly food is digested. It makes those taking it feel fuller for longer – and therefore less hungry. If the jab is recommended by a healthcare professional, those using it will need to eat a balanced, reduced-calorie diet and to exercise regularly while taking it, according to the NHS website. Who might be eligible for the drug? In the first year of the programme, the drug will be offered to people with a body mass index (BMI) score of more than 40 who have at least four other health problems linked to obesity, such as type 2 diabetes; high blood pressure; heart disease; and obstructive sleep apnoea. It was previously only accessible to patients through a special weight loss service, to severely obese people who also suffer from a range of other health problems. Estimates suggest around 1.5 million people in the UK are already taking weight loss drugs, which may have been prescribed through specialist weight loss services or via private prescription. How would it be administered? The drug is usually delivered through a self-administered weekly injection which a doctor or nurse will show patients how to use, the NHS website says. Who cannot take tirzepatide? Mounjaro is not recommended for those who are pregnant or planning to get pregnant, breastfeeding or have certain health conditions, according to the NHS. For those taking the contraceptive pill and using tirzepatide, the NHS recommends using an additional method of contraception, such as a condom, for the first four weeks of treatment and for four weeks after each dose increase as the contraceptive pill may not be absorbed by the body during this time. What are the potential side effects? Potential side effects of tirzepatide include nausea, vomiting, diarrhoea and constipation, according to the National Institute for Health and Care Excellence.

The Independent

2 hours ago

• The Independent

PHP outbids rival with £1.79bn takeover deal for Assura

NHS landlord Assura has backed an improved takeover offer from a healthcare investor amid the continued bidding war for the London-listed firm. Assura said on Monday that its board has agreed a £1.79 billion offer from Primary Health Properties (PHP). PHP had laid down a £1.68 billion bid last month but was outbid by a rival suitor, with a consortium led by US private equity firm KKR valuing the business at £1.7 billion. Assura's directors said they believe the fresh deal is in the 'best interests' of the medical property firm's shareholders. Both bidders have upped their offers several times in recent months to try and clinch a deal. Assura owns more than 600 buildings, including doctors' surgeries, with a portfolio valued at around £3.1 billion. It has about 80 members of staff. PHP, which is also listed on the London Stock Exchange, said it had agreed a deal worth around 55 pence per share. Ed Smith, non-executive chair of Assura, said: 'Following recent engagement between PHP and Assura, PHP has today further increased the terms of its offer, and has also addressed some of the potential risks that Assura had previously raised. 'The Assura board has always been and will remain resolutely focused on carrying out its fiduciary duties in the interest of Assura shareholders and in this context has decided to recommend this increased offer from PHP.' Harry Hyman, non-executive chair of PHP, said: 'The PHP board continues to believe in the strong strategic rationale of the combination, which will create a leading healthcare focussed listed REIT (Real Estate Investment Trust) with the scale and expertise to deliver significant benefits for the shareholders in PHP and Assura. 'The Increased PHP offer, which is expected to deliver earnings accretion to both sets of shareholders, allows Assura shareholders to participate in significant upside compared to crystalising value in cash at an inflexion point in the current economic cycle, and benefit from the combined group's likely long-term rating, continuing capital growth and a growing dividend.'

The Guardian

2 hours ago

• The Guardian

Is it true that … power poses boost your confidence?

You may have noticed it before: someone standing feet apart, hands on hips, chest out. Or maybe you've done it yourself before a job interview or big presentation. This is 'power posing' – the idea that striking a bold posture can make you feel more confident and improve performance. But does it work? The concept took off in the early 2010s. 'A few studies seemed to show if you expanded your body position, it would change your psychological state,' says Professor Ian Robertson of Trinity College Dublin and author of How Confidence Works. 'Other studies showed that it could alter testosterone levels, boosting motivation.' But science has since cooled on the claims. 'Subsequent meta-analyses haven't confirmed this as a reliable effect,' Robertson explains. Still, something interesting has emerged from more robust studies. While there's limited evidence that making yourself bigger directly boosts confidence, there is strong evidence that making yourself smaller can have the opposite effect. Slumping in your seat, hunching shoulders or folding into yourself can make you feel less bold. 'If you sit at a meeting in a crouched or huddled position, making yourself small, it affects both your emotion and your performance. You're less likely to persist through difficult problems. Your mood is lower and you feel less confident.' Sign up to Inside Saturday The only way to get a look behind the scenes of the Saturday magazine. Sign up to get the inside story from our top writers as well as all the must-read articles and columns, delivered to your inbox every weekend. after newsletter promotion This taps into a broader field of psychology called embodiment, which explores how physical postures and movements are closely linked to emotional states. When we're angry, we expand. When we're fearful, we shrink. These physical responses are not just outward signs of emotion – they may also feed back into our brains, reinforcing the feelings themselves. Our emotional circuits and our physical expression circuits are tightly wired together, says Robertson. So if you fake the posture of an emotion, you may actually start to feel it. 'There's a reason that 'holding your head high' has long been emphasised in military training and finishing schools.'